FeedbackThe recommendations for the treatment of DR-TB that are presented in this document have been derived from earlier WHO guideline documents (Box 1), and a WHO guideline development conducted in June 2024. These recommendations supersede the WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment, that were published in 2022 (3).
The recommendations are presented in Table B below and labelled as either a new recommendation (where based on a review of new evidence) or a reprinted recommendation (where no new evidence was available or searched for the review).
Table B. List of recommendations in the 2025 edition, where (a) is a new recommendation based on review of the new evidence and (b) is a reprinted recommendation where no new evidence was available or searched for the review
20 Imipenem–cilastatin and meropenem are administered with clavulanic acid, which is available only in formulations combined with amoxicillin. Amoxicillin–clavulanic acid is not counted as an additional effective TB agent, and it should not be used without imipenem– cilastatin or meropenem.